Estonian biotech ÄIO has secured approximately €2 million from the Estonian Ministry of Economic Affairs and Communications to scale fermentation-derived oils and fats for cosmetics and adjacent consumer applications. The funding backs the DigiFoundry 2.0 (DF2.0) project, which runs through 30 June 2029.

What is DF2.0 building?

DF2.0 centres on an integrated digital biomanufacturing platform designed to convert local food and wood industry side-streams into high-value personal care ingredients. The technical scope includes:

• Improved precision fermentation strains and processes
• Automation of upstream and downstream operations
• Digital process control and data integration
• Advanced biotechnology for yield and cost optimisation

For cosmetic buyers and formulators, the project targets production economics rather than a single molecule. The bet is that fermentation-based fats can compete with plant-derived equivalents on price, sensory profile and carbon footprint once digital scale is in place.

Who is behind it?

ÄIO is partnering with TFTAK, the Estonian applied research organisation that ran the original DigiFoundry programme between 2023 and 2026. That predecessor project delivered pilot-scale precision fermentation, sensory work and a first techno-economic assessment of specialised fat production. DF2.0 inherits that dataset and layers automation and digital control over it.

Professor Petri-Jaan Lahtvee, co-founder and COO of ÄIO, framed the work in operational terms.

"DF2.0 is about turning side-streams into the oils of tomorrow," Lahtvee said. "With digitalisation and automation, we can make that transformation faster, smarter, and more competitive and build a new generation of ingredients produced locally from resources we already have."

Why does this matter for formulators and procurement?

Three trade-relevant signals stand out:

• Feedstock independence. Wood and food side-streams anchor supply to Estonian forestry and agri-food chains, reducing exposure to imported vegetable oil volatility — palm, coconut and shea pricing swings, for example.
• INCI positioning. Fermented alternatives typically align with "bioferment" or microbial-process INCI nomenclature, which buyers can list on-pack without genetically modified organism disclosure in the EU. That keeps clean-beauty and natural-origin marketing claims intact.
• Sensory data pipeline. The original DigiFoundry included sensory analysis, a signal that ÄIO intends to deliver fermentation oils with documented skin feel and texture profiles rather than commodity substitutes.

What does the €2m actually fund?

The grant covers platform build-out, not commercial plant output. Expect capital deployment toward bioreactor automation, sensor arrays, and digital twin development through mid-2029. Procurement teams tracking ÄIO should treat the 30 June 2029 endpoint as the earliest credible inflection point for commercial-volume samples rather than an immediate buying opportunity.

What to watch next

The next concrete data points will be strain productivity disclosures and any sensory or techno-economic update published by TFTAK or ÄIO as DF2.0 milestones land. Watch list item: pilot outputs for branded variants made public before mid-2027, which would signal the project is moving from platform development to ingredient qualification.